Affimed to Present at the 39th Annual J.P. Morgan Healthcare Conference

Heidelberg, Germany, January 11, 2021 – Affimed N.V.

Rhea-AI Summary

Heidelberg, Germany, January 11, 2021 – Affimed N.V. (Nasdaq: AFMD) announced that CEO Dr. Adi Hoess will present at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021, at 7:30 a.m. EST. A live webcast of the presentation will be available on Affimed’s website for 30 days post-event. Affimed focuses on immuno-oncology, developing therapies like AFM13 for CD30-positive relapsed/refractory peripheral T cell lymphoma and AFM24 for advanced EGFR-expressing solid tumors. For details, visit Affimed’s investor site.

Argus Session date unavailable

+1.62% session move Open Argus

Details

News Market Reaction – AFMD

The recorded move for AFMD in the trading session of this news was +1.62%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Heidelberg, Germany, January 11, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that its Chief Executive Officer, Dr. Adi Hoess, will present at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2021 at 7:30 a.m. Eastern Standard Time.

A live webcast of the presentation may be accessed on Affimed’s website at https://www.affimed.com/investors/webcasts_cp/ and will be available for 30 days following the event. For more information or to schedule a one-on-one meeting with Affimed management, please contact Alex Fudukidis via email at a.fudukidis@affimed.com or phone at +1 (917) 436-8102.

About Affimed N.V.

Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer. Affimed’s fit-for-purpose ROCK® platform allows innate cell engagers to be designed for specific patient populations. The company is developing single and combination therapies to treat hematologic and solid tumors. The company is currently enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T cell lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. For more information, please visit www.affimed.com.

Investor Relations Contact

Alex Fudukidis
Head of Investor Relations
E-Mail: a.fudukidis@affimed.com
Tel.: +1 (917) 436-8102

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Affimed's CEO presenting at the J.P. Morgan Healthcare Conference?

Affimed's CEO, Dr. Adi Hoess, will present on January 14, 2021, at 7:30 a.m. EST.

Where can I watch Affimed's presentation at the J.P. Morgan Healthcare Conference?

You can watch the live webcast on Affimed’s website, and it will be available for 30 days after the event.

What is Affimed's focus in the immuno-oncology sector?

Affimed focuses on developing therapies that enhance the innate ability of patients to fight cancer, including treatments for hematologic and solid tumors.

What therapies is Affimed currently developing?

Affimed is developing AFM13 for CD30-positive relapsed/refractory peripheral T cell lymphoma and AFM24 for advanced EGFR-expressing solid tumors.

How can I contact Affimed for investor relations?

You can contact Alex Fudukidis via email at a.fudukidis@affimed.com or by phone at +1 (917) 436-8102.